Imatinib is the leading compound to treat patients with chronic myelogenous leukemia (CML) but the exact mechanism of its anti-leukemic effect is incompletely elucidated. Through inhibition of BCR-ABL, Imatinib blocks several downstream pathways and induces apoptosis of BCR-ABL positive cells. In this study, we analyzed further the mode of action of Imatinib in different appropriate cellular models of CML either sensitive or resistant to Imatinib and in CD34 þ cells from CML patients. Pharmacological or short hairpin RNA-mediated inhibition of BCR-ABL triggers lysosomal membrane permeabilization (LMP) that culminates in activation and redistribution of Cathepsin B (CB) into the cytoplasm of CML cells, in which it triggers directly BCR-ABL degradation. Pharmacological inhibition of CB by CA-074Me or small interfering RNAmediated knock-down of CB partly protects K562 cells from Imatinib-induced cell death and CB overexpression sensitizes these cells to Imatinib killing. Strikingly, Imatinib-triggered LMP, CB activation and BCR-ABL cleavage in CD34 þ cells from CML patients and inhibition of CB confers protection against cell death in clonogenic assays of CD34 þ primary cells from CML patients. Hence, we describe an original pathway by which Imatinib participates to the elimination of CML cells through LMP and CB-mediated specific degradation of BCR-ABL.
Introduction
Chronic myelogenous leukemia (CML) is caused by the t(9;22) (q34;q11) translocation encoding the constitutively activated p210BCR-ABL tyrosine kinase, which is necessary for leukemogenesis.
1,2 P210BCR-ABL activates numerous downstream pathways including PI3K/Akt, P42/44MAPK, STAT5-Bcl-Xl and NFkB conferring increased proliferation and inhibition of apoptosis. 3, 4 Imatinib mesylate has emerged as the leading compound to treat patients with CML. 5, 6 However, a nonnegligible proportion of patients in chronic phase and significant percentage with advanced-stage disease are refractory to Imatinib therapy. One of the major effects of Imatinib in CML cells is to induce mitochondria-dependent apoptosis through caspase activation, an effect that essentially relies on Bim activation. 7, 8 However, the anti-leukemic effect of Imatinib is only partly inhibited by caspase inhibitors suggesting that other modes of cell death are involved. Along with others, we have shown that in the presence of caspase inhibitors, although apoptosis is abrogated, CML cell death may occur independently of caspases. 9, 10 In addition to mitochondria, there are compelling evidence that other organelles such as lysosomes and endoplasmic reticulum are involved in cell death processes. 11, 12 Lysosomes are intimately associated with apoptotic cell death and several anticancer drugs can trigger lysosomal membrane permeabilization (LMP) in different cell types. 13 As a part of this pathway, LMP allows the release of cathepsins into the cytoplasm.
Several studies suggest that LMP leads to mitochondrial membrane permeabilization through Bid cleavage by lysosomal cathepsins. [14] [15] [16] Another mode of cell death that could occur in some circumstances in CML cells is autophagic cell death or type II cell death. Indeed, a recent study evidenced that INNO-406, a dual Src kinase and BCR-ABL inhibitor, triggers autophagy in CML cell lines provided that caspases are inactivated. 17 The aim of this study was to analyze further the complex antileukemic effect of Imatinib in CML cell lines and CD34 þ cells isolated from CML patients regarding the induction of different cell death modes including lysosomal and autophagic cell death. We show that inhibition of BCR-ABL triggers LMP that culminates in the redistribution of Cathepsin B (CB) from a lysosomal to a cytoplasmic localization in CML cell lines. Pharmacological inhibition or small interfering RNA (siRNA)-mediated knock-down of CB protects CML cell from Imatinibinduced cell death through impairment of CB-dependent cleavage of BCR-ABL. Finally, Imatinib induces CB activation in CD34 þ cells from CML patients and inhibition of CB in CD34 þ cells confers protection against Imatinib-mediated cell death. For the first time, our findings show that CB release after Imatinib-mediated LMP triggers BCR-ABL cleavage and inactivation that participates to elimination of CML cells.
Materials and methods

Reagents and antibodies
Imatinib mesylate (Glivec) was kindly provided by Novartis Pharma (Basel, Switzerland). RPMI 1640 medium and fetal calf serum were purchased from Gibco BRL (Paisley, UK). Sodium fluoride, sodium orthovanadate, phenylmethylsulfonyl fluoride, aprotinin and leupeptin, were from Sigma (St Louis, MO, USA). z-RR-AMC was from Alexis Biochemicals (Lausanne, Switzerland). CA-074Me and rapamycin were purchased from Calbiochem (Darmstadt, Germany). Anti-ABL, VDAC, HSP60 and BCR antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-phospho-ABL was from Cell Signaling Technology (Danvers, MA, USA). Anti-LC3 antibody was purchased from Novus Biological (Littleton, CO, USA) and anti-CB provided by Calbiochem. HRP conjugated anti-mouse, rabbit and goat antibodies were from Dakopatts (Glostrup, Denmark).
Cell lines
K562 cells were grown at 37 1C under 5% CO 2 in RPMI 1640 medium (Gibco BRL) supplemented with 5% fetal calf serum, 50units/ml penicillin, 50 mg/ml streptomycin and 1 mM sodium pyruvate. K562-resistant cell lines have been described earlier. ) were grown in RPMI 1640 medium containing 10% fetal calf serum under 5% CO2. K562 cells stably expressing a short hairpin RNA (shRNA) directed against BCR-ABL has been described earlier. 19 
Primary cells isolation
Blood samples were collected from patients newly diagnosed for CML as part of an institutionally approved cellular sample collection protocol. Informed consent has been obtained according to institutional guidelines. Mononuclear cells were isolated from blood samples by density centrifugation (FicollPaque Plus; StemCell, Vancouver, BC, Canada), washed with phosphate buffered saline, 5% FCS fetal calf serum (SVF), 2 mM ethylene-diaminetetraacetic acid and resuspended in cell culture medium (Iscove's Modified Dulbecco's Medium (IMDM), 10% fetal bovine serum) and incubated overnight at 37 1C in a 5% CO 2 incubator before CD34 þ cells isolation. CML cells were labeled with CD34 microbeads isolated by magnetic positive selection (StemSep Human CD34 Selection Kit; StemCell, Vancouver, BC, Canada). Experiments were performed using a StemSpan SFEM medium (StemCell) supplemented with 100 ng/ml human recombinant stem cell factor (SCF), FMS-like Tyrosine Kinase 3-Ligand (FLT3-L) and 20 ng/ml human recombinant interleukin-3, interleukin-6 and granulocyte CSF (Peprotech, Rocky Hill, NJ, USA).
Cathepsin B activity measurement
After stimulation, cells were lysed for 30 min at 4 1C in lysis buffer (0,4 M Na Phosphate pH 6, 150 mM NaCl, 4 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin and 1% Triton X-100) and lysates were cleared at 10 000 g for 15 min at 4 1C. Each assay (in quadruplicate) was performed with 50 mg of protein prepared from control or stimulated cells. Briefly, cellular extracts were incubated in a 96-well plate, with 60 mM of z-RR-AMC (7-amino-4-methylcoumarin) as substrate for various times at 37 1C. CB activity was measured by following emission at 460 nm (excitation at 390 nm) in the presence or absence of 1 mM of CA-074Me. Enzyme activities were expressed in arbitrary unit per mg of protein.
Western blot
Western blot analysis have been described earlier. 19 
Assessment of lysosomal membrane permeabilization by flow cytometry
To label lysosomes, LysoTracker-Green or acridine orange (Invitrogen, South Washington, DC, USA) was used at a final concentration of 75 nM or 1 mg/ml, respectively. The cells induced for various time with different effectors were incubated for 30 min at 37 1C with LysoTracker, resuspended in phenolfree RPMI 1640, 10% fetal calf serum medium and analyzed using a FACScan (Becton Dickinson, Cowley, UK).
Confocal microscopy
Red fluorescence protein (RFP)-LC3 construct was stably transfected in K562 cells. After treatment with Imatinib, cells were incubated with 1 mg/ml DAPI (and/or 75 nM LysoTracker for 30 min as described earlier), washed three times with phosphate buffered saline and mounted on glass slides in Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL, USA), examined and photographed using a confocal laser microscope (CarlZeiss, Munich, Germany).
Preparation of cytosolic and lysosomal fractions
Cytoplasmic and lysosomal fractions were prepared using a ProteoExtract -Subcellular Proteome Extraction Kit (Calbiochem) according to the manufacturer's instructions. The purity of each fraction was analyzed by immunoblotting using antibodies against Tubulin-g (cytoplasmic fraction) and LAMP-2 (lysosomal fraction).
In vitro transcription/translation of p145Abl
A pcDNA3 encoding p145Abl vector was transcribed and translated using the Promega TNT Quick coupled reticulocyte lysate system (Promega, Madison, WI, USA) as described earlier. 19 After transcription/translation, 5 ml of reticulocyte lysate were incubated in CB buffer.
In vitro cleavage assay
In vitro cleavage of BCR-ABL and ABL were performed in 30 ml cleavage buffer (100 mM NaCl, 400 mM Na Phosphate pH 6, 1 mM ethylene-diaminetetraacetic acid, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 10 mM dithiothreitol and 0.1% 3((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate (CHAPS)) containing 50 mg of protein extract or 5 ml reticulocyte lysate containing transcribed/translated p145Abl. Human recombinant CB (Calbiochem) was added with or without 1 mM CA-074Me. Samples were incubated at 37 1C for 16 h, separated on 7% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotted with an anti-ABL antibody.
BCR-ABL immunoprecipitation
K562 cells were resuspended in lysis buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 20 mM ethylene-diaminetetraacetic acid, 1 mM dithiothreitol, 50 mM NaF, 0.1 mM Na 3 VO 4 , 1mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin and 0.5% Nonidet P-40). Lysates (500 ml) were incubated with 1.5 mg of polyclonal anti-BCR antibody and 30 ml of protein G-Sepharose (Zymed Laboratories, San Francisco, CA, USA) at 4 1C overnight. Beads were washed five times with 1 ml of lysis buffer and resuspended in cleavage buffer.
Overexpression of Cathepsin B
K562 cells were transiently transfected with pcDNA3-CT or pcDNA3-CB (a generous gift from Professor S Grimm and Dr A Lysosomal release of CB triggers BCR-ABL cleavage A Puissant et al Gewies) using the jetPEI protocol (PolyPlus Transfection Inc., New-York, NY, USA). One day after transfection with control or CB plasmids (2.5 mg), cells were treated or not with Imatinib for 2 supplemental days.
Knock-down of CB and LC3 by siRNA
Stealth siRNAs targeting CB were purchased from Invitrogen whereas LC3 siRNA were purchased from Dharmacon (Lafayette, CO, USA). K562 cells were transfected with different siRNAs at the final concentration of 50 nM using the Lipofectamine RNAimax protocol (Invitrogen). Cells were harvested 2 or 4 days after the beginning of the transfection for protein expression. For others experiments, 2 days after transfection, cells were treated or not with Imatinib for 2 supplemental days.
Cell viability assay
Cells (15 Â 10 3 cells/100 ml or 45 Â 10 3 primary CD34 þ cells/ 100 ml) were incubated in a 96-well plate with different effectors for the indicated times. Cell viability assay has been described earlier. 19 
Colony formation assay
Effectors were added to K562 cells (0.5 Â 10 3 cells/ml) or primary cells (10 3 CD34 þ cells/ml) growing in semisolid methyl cellulose medium. MethoCult H4100 or H4236 were used for cell lines and primary CD34 þ cells respectively (StemCell Technologies Inc., Vancouver, BC, Canada). Colony formation assays have been reported elsewhere. 20 
Statistical analysis
Results are expressed as the mean ± s.d. Statistical analysis was performed using the Student's t-test with Po0.05 deemed as statistically significant. All experiments were repeated at least three times unless otherwise stated.
Results
Pharmacological inhibition or knock-down of BCR-ABL triggers CB activation
We 10,20,21 and others [22] [23] [24] have reported that Imatinib induces mitochondria-dependent apoptosis in CML lines but to our knowledge, besides caspases, no other proteolytic activities have been associated with the effect of this BCR-ABL inhibitor 
Cathepsin B activation by Imatinib is accompanied by its cytoplasmic redistribution
Cathepsins are cysteine proteinases, which participate to the degradation and recycling of proteins into the lysosome. 25 We, therefore, analyzed whether Imatinib-mediated CB activation was accompanied by redistribution of CB activity. To this end, IM-S and IM-R cells were treated for 48 or 72 h with Imatinib and fractionated into cytoplasmic and microsomal extracts (Figures 2a and b) . Imatinib treatment resulted in a dosedependent decrease of CB activity associated with the lysosomal fraction together with a parallel increase in cytoplasmic CB. At 72 h, all the CB activity was associated with the cytoplasmic fraction in IM-S but not in IM-R cells (Figure 2b ).
Imatinib induces LMP in IM-S but not IM-R K562 cells
As Imatinib-triggered redistribution of CB into the cytoplasm of CML cells, we reasoned that it may affect LMP in K562 cells. Thus, we treated IM-S and IM-R cells for 48 or 72 h with 1 or 3 mM Imatinib before the addition of two dyes specifically labeling lysosomes, the green LysoTracker DND-189 and the red acridine orange. Imatinib induced a time and dosedependent decrease of LysoTracker and acridine orange fluorescence in IM-S cells reflecting a loss of lysosomal integrity consecutive to LMP (Figure 3a) . It also triggered LMP in Baf/3-p210WT cells but not in Baf/3-p210T315I cells, which are resistant to Imatinib (Figure 3b ). In addition, BCR-ABL knock-down by shRNA also mediated LMP (Figure 3c ). Induction of LMP by Imatinib was confirmed by the loss of the punctate LysoTracker-Green fluorescence in K562 cells using fluorescent microscopy ( Figure 3d) . As a whole, these findings show that inhibition of BCR-ABL expression or activity triggers LMP in IM-S but not IM-R cells. Recently, Imatinib and INNO-406 were reported to induce autophagy in neuroblastoma and CML cell lines, respectively. 17, 26, 27 In our hands, Imatinib induced neither conversion of LC3-I to LC3-II as assessed by western blotting (Supplementary Figure 1a) nor relocation of RFP-LC3 to autophagosomes (Supplementary Figure 1b) as compared with rapamycin used as a positive control of autophagy. In addition, knock-down of LC3 by siRNA failed to modulate the effect of Imatinib on cell metabolism in IM-S and IM-R K562 cells indicating that autophagy is not required for its anti-leukemic effect ( Supplementary  Figures 1c and d) . In addition, Imatinib-triggered autophagy in Baf3-p210WT and Baf3-p210T315I cells as well ( Supplementary  Figure 2a) , showing that, in these cell line, the Imatinib effect was independent on BCR-ABL. By contrast, Imatinib-mediated CB activation was detected in Baf3-P210WT cells only.
p210BCR-ABL is a substrate for CB in vitro and in intact cells
To date, besides Bid, identification of CB substrates has remained elusive.
14 To test whether BCR-ABL could be /ml) were incubated in the presence of 1 mM Imatinib for 48 h and analyzed as described in panel (a and c) K562 cells expressing an inducible short hairpin RNA (shRNA) directed against green fluorescent protein (GFP) or BCR-ABL were incubated for 0, 3, 5 or 7 days with tetracycline (1 mg/ml) to induce BCR-ABL silencing and next analyzed as described in panel (a and d) K562 cells were stimulated with 3 mM Imatinib, labeled with LysoTracker-Green and DAPI and analyzed by confocal microscopy.
Lysosomal release of CB triggers BCR-ABL cleavage A Puissant et al substrate for CB, we subjected cytoplasmic extracts from K562 cells to increasing concentrations of recombinant CB for 16 h in either the absence or presence of the CB inhibitor CA-074Me, the pan-caspase inhibitor zVAD-fmk or the combination of both (Figures 4a and b) . BCR-ABL degradation was, then, assessed by western blot using a specific anti-ABL antibody. As illustrated on Figure 4a , p210BCR-ABL and p145ABL were efficiently cleaved by CB giving rise to 37-kDa and 55-kDa fragments, respectively. The CB-derived 55-kDa fragment was further degraded in two products at 37 kDa. CB-mediated p210BCR-ABL cleavage was abolished by CA-074Me but not by zVAD-fmk ruling out the possibility that caspases could be responsible for CB activation (Figure 4b ). We also confirmed by both transcription/translation analysis and immunoprecipitation experiments that ABL and P210BCR-ABL were direct substrates for CB, respectively (Figures 4c and d) . Cleavage of p210BCR-ABL and its inhibition by CA-074Me were observed also in intact K562 cells treated with Imatinib (Figure 4e) . Furthermore, knock-down of CB with two specific siRNAs abolished p210BCR-ABL cleavage showing that this chimaeric tyrosine kinase is a CB substrate in intact CML cells (Figure 4f ).
Inhibition of Cathepsin B increases cell viability in the presence of Imatinib
We, next, analyzed whether CB activation participated in Imatinib-mediated loss of cell viability of K562 cells. CA-074Me reduced Imatinib-mediated loss of cell clonogenicity (Figure 5a ). In addition, two different siRNAs that abrogated CB expression (Figure 5b ) augmented cell viability in the presence of Imatinib confirming the participation of CB in the loss of cell viability mediated by this tyrosine kinase inhibitor (Figure 5c ). Finally, overexpression of CB sensitized K562 cells to Imatinib-mediated cell death (Figure 5d ). Interestingly, CA074Me was more efficient to inhibit cell metabolism in CB overexpressing cells than in control cells (Figures 5d and e) . Increased viability correlated with a complete inhibition of Imatinib-induced CB activity and did not rely on modification of P210BCR-ABL phosphorylation by CA-074Me ( Supplementary  Figures 3a and b) .
Death of CD34 þ CML cells is associated with LMP and increase of CB activity
To analyze whether CB activation is a relevant determinant of the anti-leukemic effect of Imatinib in patients, we tested the ability of CA-074Me to inhibit Imatinib-mediated death of CD34 þ progenitors from patients with CML. The characteristic of the different patients are depicted in Supplementary Table 1. CD34 þ cells were purified on magnetic beads coated with anti-CD34 monoclonal antibody. For each patient the purity of CD34 þ estimated by fluorescence-activated cell sorting was found to be at least 90%.
Cells were next grown in methylcellulose and the number of colony-forming cells was evaluated. The results presented in Figure 6a represent the mean of five samples from different CML In some conditions, protein extracts were treated with zVAD-fmk (50 mM) or CA-074Me (1 mM) or the combination of both. BCR-ABL and ABL proteins levels were analyzed as in (a and c) BCR-ABL protein was immunoprecipited from IM-S K562 cells using a specific anti-BCR antibody. After washing, immunoprecipitate was incubated for 8 h at 37 1C with different concentrations of recombinant CB in the presence or absence of 1 mM CA-074Me. After digestion, immunoprecipitates and supernatants were analyzed, by western blot, using anti-ABL antibody. (d) p145ABL was transcribed and translated in vitro and incubated for 16 h at 37 1C with different concentrations of recombinant CB in the presence or absence of 1 mM CA-074Me. ABL was detected, by western blot, using anti-ABL antibody. *indicates likely a shorter transcript of ABL. (e) K562 cells were treated for 48 h with 3 mM Imatinib in the presence or absence of CA-074Me (2.5 mM). BCR-ABL and ABL proteins levels were visualized by western-blot. (f) K562 cells (10 5 /ml) were transfected for 4 days with a control small interfering RNA (siRNA) (siCT) or two siRNAs specifically directed against CB (siCB 1 and 2). Imatinib (1 or 3 mM) was added for the last 2 days. BCR-ABL, ABL and CB levels were analyzed by western blot using specific antibodies. HSP60 was used as a loading control.
patients. It seems clear from this experiment that specific inhibition of CB increased CD34 þ CML cell viability in the presence of Imatinib.
Inhibition of Imatinib-induced caspase activation was found to increase viability to roughly the same extent as CA-074Me, confirming the notion that CB mediated a significant part of the Imatinib effect on CD34 þ progenitors cell death (Figure 6b ). On the basis of the fact that CA-074Me inhibits Imatinibinduced loss of CD34 þ CML cell viability and that it also triggered LMP, we analyzed whether this agent might induce CB activation in CD34 þ progenitors from CML patients. Figure 6c showed that 3 mM Imatinib induced a threefold increase in CB activity in mononuclear cells from CML patients, which is close to the situation observed in CML cell lines (Figure 1a) . We also verified, in one patient that Imatinib did induce p210BCR-ABL cleavage in its characteristic 55-kDa fragment and increased also expression of active CB (Figure 6c ). In addition, Imatinib was capable to trigger LMP and CB release in CD34 þ CML cells isolated from three different patients (no. 5, no. 6, no. 7) (Figure 6d ).
Discussion
Although Imatinib has emerged as the leading compound to treat patients with CML, the mechanisms underlying its complex anti-leukemic effects are incompletely understood. In this study, we showed that Imatinib triggers LMP and CB redistribution into the cytoplasm of CML cell lines and CD34 þ cells from CML patients. Interestingly, BCR-ABL knock-down by shRNA mimicked the effect of Imatinib on LMP, confirming that BCR-ABL inhibition is responsible for induction of LMP in CML cells. In addition, we showed that induction of LMP-triggered redistribution of CB to the cytoplasm of Imatinib-treated CML cells in which it degraded directly p210BCR-ABL. To the best of our knowledge, this is the first demonstration that Imatinib mediates LMP in CML cells and that BCR-ABL is a direct substrate of CB.
It has been reported that Imatinib may induce autophagic cell death in a neuroblastoma cell line overexpressing a BCR-ABL construct. 26 Conversely, in a recent study, Bellodi et al.
27
showed that Imatinib induces autophagy in CML blast crisis cell lines and that inhibition of autophagy genes may enhance cell death induced by Imatinib. Our findings show that, in K562 cells, Imatinib induces neither autophagic cell death nor protective autophagy. In addition, although Imatinib does induce autophagy in Baf/3 murine myeloïd cells, this occurs in cells expressing WT p210 and T315I BCR-ABL as well, showing that this process is independent on BCR-ABL. It is admitted that cathepsins failed to activate executioner caspases directly. 28 Rather, they triggered caspase-dependent cell death through cleavage of Bid, 14 which can induce the Lysosomal release of CB triggers BCR-ABL cleavage A Puissant et al release of cytochrome C from mitochondria and the subsequent activation of caspases. In non-apoptotic conditions, cathepsins are sequestered into the lysosomes of intact cells in which they participate to the normal turnover of proteins and as such has an important role in the regulation of basal autophagy. 29 Once into the cytoplasm, CB is supposed to induce cell death through the degradation of specific protein substrates. To date, besides Bid, the identification of cathepsin substrates has remained elusive.
Recently, Droga-Mazovec et al. 16 reported that Bcl-2 family members are substrates for cathepsins in vitro and suggested that degradation of Bax, Mcl-1 and Bcl-Xl by cathepsins may have a role in the regulation of apoptosis. We reasoned that, in the context of CML, BCR-ABL might be an attractive candidate for CB cleavage because every modulation of BCR-ABL expression is expected to affect on CML cell death and survival. It is known that caspase-mediated degradation of BCR-ABL contributes to increase induction of apoptosis. 20, 30 We, therefore, analyzed the ability of CB to cleave p210BCR-ABL. We found that BCR-ABL is cleaved directly by CB in vitro and in intact cells. Moreover, knock-down of CB by specific siRNAs abolished the cleavage of BCR-ABL mediated by Imatinib and confered protection against Imatinib-mediated cell death. Altogether, our data establish that CB has an important role in Imatinib-induced CML cell death through the cleavage of BCR-ABL.
These data are reminiscent of those by Kitareewan et al. 31 who reported recently that in an acute promyelocytic leukemia cell line, arsenite induces the destabilization of lysosomes and the subsequent release of cathepsin L (CL) into the cytoplasm, leading to the degradation of the promyelocyte-retinoic acid receptor (PML-RARa) fusion protein. These results strongly suggest that cleavage of fusion proteins involved in diverse leukemia such as PML-RARa and BCR-ABL may be a general mechanism for the anti-leukemic effect of cathepsins. We finally, analyzed the consequence of Imatinib-induced CB redistribution on cell viability. In a first approach, we established that abrogation of CB activity by CA-074Me Photographs of a significant culture treated for 14 days are also shown. (b) CD34 þ primary cells were preincubated for 1 h in the presence or the absence of either zVAD-fmk (50 mM) or CA-074Me (2.5 mM) and next exposed to Imatinib (1 mM) for the next 48 h. Cell viability was assessed using the XTT assay. Results represent the mean±s.d. of four different determinations. (c) Mononuclear cells from four newly diagnosed patients were incubated in the presence of Imatinib (1 mM) for 48 h. CB activity was measured in quadruplicates using z-RR-AMC as substrate. Results represent the mean ± s.d. of four different determinations. BCR-ABL and CB level were also analyzed by western blot for one patient using anti-ABL and anti-CB antibodies. HSP60 was used as a loading control. (d) CD34 þ primary cells isolated from three newly diagnosed patients were incubated in the presence of Imatinib (1 mM and 3 mM) for 48 h. Lysosomes integrity was determined by flow cytometry using LysoTracker-Green as described earlier.
(a-d) Error bars ¼ 95% confidence intervals. *Po0.05 was considered as statistically significant. increased significantly cell viability in the presence of Imatinib in both K562 cells and CD34 þ progenitors from CML patients. In a second one, we provided evidence that knock-down of CB favors CML cell survival in the presence of Imatinib. Accordingly overexpression of CB was found to sensitize K562 cells to Imatinib-mediated cell death, an effect strongly inhibited by CA074Me. Taken together, our results show that CB release after Imatinib-mediated LMP is an important determinant of its antileukemic effect through induction of BCR-ABL cleavage.
On a clinical point of view our findings may have important implications. Indeed, induction of lysosomal cell death has been suggested as a possible alternative to eradicate tumor cells. 13, 32 In this line, Ivanov et al. 33 , recently reported that two clinically relevant monoclonal antibodies, namely the specific CD20-specific mAb tositumomab and an HLA-DR-specific mAb elicit cell death in human lymphoma cell lines and primary chronic lymphocytic leukemia, respectively, through a lysosome-dependent pathway. Importantly, this cell death mode could be inhibited by Bafilomycin A1 and cathepsin inhibitors.
Therefore, identifying compounds capable of activating the lysosomal cell death pathway may be an important challenge for the treatment of CML and other hematopoietic malignancies.
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